Sumary of Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis:
- COVID-19 predominantly causes respiratory illness but, in some cases, may also affect the cardiovascular system and cause myocarditis..
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE-2) receptor present on the surface of cardiac cells, which likely explains the direct cardiac involvement in COVID-19 patients..
- Myocarditis and its clinical presentation in COVID-19 Myocarditis is an inflammatory disease that has both infectious and non-infectious etiologies..
- The most severe type of myocarditis is fulminant myocarditis, which is predominantly caused by viral infections..
- Fulminant myocarditis is characterized by severe and sudden inflammation of the myocardium that leads to cardiogenic shock, ventricular bradyarrhythmias or tachyarrhythmias..
- Although the clinical presentation of COVID-19 patients with myocarditis varies greatly, the usual symptoms include chest pain, fatigue, acute heart failure, and cardiogenic shock..
- Previous studies have reported increased levels of inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lactate, and procalcitonin..
- Several electrocardiogram (ECG) abnormalities are seen in myocarditis patients ranging from PR depression and ST elevation to new-onset bundle branch block, brady- or tachyarrhythmias, and QT prolongation….